CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at

Expected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications April restructuring to advance corporate strategy and pipeline expected to result in approximate annualized cost savings of $170M , with significant portion related to

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast

Changes are expected to result in annualized cost savings of approximately $170 million , including SG&A savings of $150 million Headcount reduction of 340 – approximately 53 percent of workforce Current balance of cash, cash equivalents, restricted cash, and marketable securities expected to

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on April 1, 2020 , the

Expected regulatory pathway for episodic treatment of major depression remains unchanged with plan for one new additional efficacy study Pursuing two additional pathways with the goal of accelerating patient access to zuranolone while continuing development for the episodic treatment of depression

CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on March 2, 2020 , the Compensation

ZULRESSO™ (brexanolone) CIV injection net revenues of $2M and $4M for fourth quarter and full year 2019, respectively Evaluating path forward for the zuranolone (SAGE-217) Landscape Program Continued expansion of Neurology and Neuropsychiatry franchises with planned initiation of additional

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at